Heuser Patricia, Tonga Katrina, Hopkins Raewyn, Henderson Marissa, Weatherall Mark, Metcalfe Scott, Beasley Richard
Medical Research Institute of New Zealand, Wellington, New Zealand.
N Z Med J. 2004 Nov 26;117(1206):U1176.
To determine whether there is an increased risk of venous thromboembolism (VTE) with anti-androgen oral contraceptives containing cyproterone acetate and ethinyloestradiol.
Comparison of the frequency of specific oral contraceptive use in patients aged 15 to 55 years discharged from hospital with radiologically confirmed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) with the expected frequency of use derived from national prescription data.
Ratio of observed frequency of specific oral contraceptive use in patients with VTE versus expected frequency of use.
The rank order for observed versus expected use was anti-androgen > third-generation, > second-generation, > progestogen-only oral contraceptive agents with ratios of 1.93, 1.36, 0.70, and 0.39, respectively.
The risk of VTE resulting in hospital admission associated with anti-androgen oral contraceptive use is at least as high as with third generation use.
确定含醋酸环丙孕酮和炔雌醇的抗雄激素口服避孕药是否会增加静脉血栓栓塞（VTE）风险。
比较15至55岁因放射学确诊深静脉血栓形成（DVT）和/或肺栓塞（PE）而出院的患者中特定口服避孕药的使用频率与根据国家处方数据得出的预期使用频率。
VTE患者中特定口服避孕药的观察使用频率与预期使用频率之比。
观察使用与预期使用的排序为抗雄激素>第三代>第二代>仅含孕激素的口服避孕药，其比值分别为1.93、1.36、0.70和0.39。
使用抗雄激素口服避孕药导致住院的VTE风险至少与使用第三代口服避孕药一样高。
